According to the findings, 36% of current GLP-1 users report currently microdosing, 32% of users say they used to microdose in the past, but have stopped, and 32% say they have never microdosed
Scientific References Ozempic 0.5 mg solution for injection in pre-filled pen
New JAMA Study Links Wegovy to NAION A JAMA study published on July 3, 2024, on the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide found an increased risk of the condition in patients taking semaglutide compared to those taking non-GLP-1 RA medications
Based on current data, GLP-1s appear generally well tolerated in people with IBD, but we do not yet have large, long-term trials in people with UC, so I tell patients we should decide together, case by case, based on their disease activity, nutritional status, and other health conditions, Dr